Outcomes of advanced gastric cancer in young adult patients treated with first-line combination chemotherapy
Purpose: Despite conflicting data regarding survival after curative surgery, little is known about the prognosis of metastatic gastric cancer (MGC) in young adults. The current study was performed to determine whether younger age is an independent prognostic factor among MGC patients receiving first-line chemotherapy and to evaluate how age relates to other known prognostic parameters.
Methods: The records of 1843 MGC patients who were consecutively treated with first-line combination chemotherapy at Samsung Medical Center (Seoul, Korea) between 2000 and 2007, including 570 patients aged 45 years or younger, were retrieved from a prospective cancer chemotherapy database.
Results: In the younger group, there were significantly more bone metastases, ascites, poor performance status, low albumin, elevated alkaline phosphatase, and resections that were non-curative than in the older patients. Progression-free survival (PFS) and overall survival (OS) was shorter in younger patients (PFS, 4.2 months; OS, 7.1 months) than in older ones (PFS, 5.1 months; OS, 8.4 months). Nonetheless, younger age did not show an independent association with PFS or OS. Stratified analyses showed that younger age was related with poor outcome in the subgroups of good performance status and no bone metastasis.
Conclusion: When matched for other prognostic factors, the prognosis of younger MGC patients receiving first-line combination chemotherapy does not differ from that of older patients. The poor survival of younger patients may be attributed to the association with other adverse prognostic factors.
Bae JM, Won YJ, Jung KW, et al. Annual report of the Korean central cancer registry program 2000: Based on Registered Data from 131 Hospitals. Cancer Res Treat. 2002;34:77-83.
Wanebo HJ, Kennedy BJ, Chmiel J, et al. Cancer of the stomach. A patient care study by the American College of Surgeons. Ann Surg. 1993;218:583-92.
Eguchi T, Takahashi Y, Yamagata M, et al. Gastric cancer in young patients. J Am Coll Surg. 1999;188:22-6.
Lai IR, Lee WJ, Chen CN, et al. Gastric cancer in the young. Hepatogastroenterology. 1997;44:1641-5.
Matley PJ, Dent DM, Madden MV, et al. Gastric carcinoma in young adults. Ann Surg. 1988;208:593-6.
Kokkola A, Sipponen P. Gastric carcinoma in young adults. Hepatogastroenterology. 2001;48:1552-5.
Santoro R, Carboni F, Lepiane P, et al. Clinicopathological features and prognosis of gastric cancer in young European adults. Br J Surg. 2007;94:737-42.
Llanos O, Butte JM, Crovari F, et al. Survival of young patients after gastrectomy for gastric cancer. World J Surg. 2006;30:17-20.
Pyrhonen S, Kuitunen T, Nyandoto P, et al. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer. 1995;71:587-91.
Glimelius B, Ekstrom K, Hoffman K, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol. 1997;8:163-8.
Wagner AD, Grothe W, Haerting J, et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006;24:2903-9.
Ohtsu A, Yoshida S, Saijo N. Disparities in gastric cancer chemotherapy between the East and West. J Clin Oncol. 2006;24:2188-96.
Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-16.
Lee J, Lim T, Uhm J, et al. Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma. Ann Oncol. 2007;18:886-91.
Nakamura K, Ueyama T, Yao T, et al. Pathology and prognosis of gastric carcinoma. Findings in 10,000 patients who underwent primary gastrectomy. Cancer. 1992;70:1030-7.
Chau I, Norman AR, Cunningham D, et al. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol. 2004;22:2395-403.
Kim JH, Boo YJ, Park JM, et al. Incidence and long-term outcome of young patients with gastric carcinoma according to sex: does hormonal status affect prognosis? Arch Surg. 2008;143:1062-7; discussion 1067.
Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. NEngl J Med. 2008;358:36-46.
Kang YK, Kang WK, Shin DB, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III non-inferiority trial. Ann Oncol. 2009;20:666-73.
Okines AF, Norman AR, McCloud P, et al. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol. 2009;20:1529-34.
This work is licensed under a Creative Commons Attribution 3.0 License.
International Journal of Cancer Therapy and Oncology (ISSN 2330-4049)
© International Journal of Cancer Therapy and Oncology (IJCTO)
To make sure that you can receive messages from us, please add the 'ijcto.org' domain to your e-mail 'safe list'. If you do not receive e-mail in your 'inbox', check your 'bulk mail' or 'junk mail' folders.